WuXi Biologics (Cayman) Inc. (HKG: 2269)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 45.74B |
| Revenue (ttm) | 18.39B |
| Net Income (ttm) | 2.83B |
| Shares Out | 4.14B |
| EPS (ttm) | 0.64 |
| PE Ratio | 17.16 |
| Forward PE | 9.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 58,606,161 |
| Open | 10.90 |
| Previous Close | 11.06 |
| Day's Range | 10.86 - 11.36 |
| 52-Week Range | 10.14 - 52.45 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 21, 2024 |
About WuXi Biologics
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufact... [Read more]
Financial Performance
In 2023, WuXi Biologics's revenue was 17.03 billion, an increase of 11.56% compared to the previous year's 15.27 billion. Earnings were 3.40 billion, a decrease of -23.09%.
Financial numbers in CNY Financial StatementsNews
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI™ in 2,000L GMP Manufacturing
By leveraging its ultra-intensified fed-batch platform, WuXiUI™, WuXi Biologics has completed its first scale-up to 2,000L drug substance (DS) GMP manufacturing, achieving a 4-fold productivity improv...
WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2024 Earnings Call Transcript
WuXi Biologics (Cayman) Inc. (OTCPK:WXXWY) Q2 2024 Earnings Conference Call August 22, 2024 8:30 AM ETCompany ParticipantsLina Fan - Senior Vice President,...
WuXi Biologics (Cayman) Inc. 2024 Q2 - Results - Earnings Call Presentation
WuXi Biologics Reports Solid 2024 Interim Results
Revenue increased by 1.0% YoY to RMB 8,574.2 million Non-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial manufacturing YoY growth of 11.7%Added 61 new integrated projects, inclu...
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispeci...
Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
Planegg/Martinsried, August 8, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and WuXi Biologics (stock code: 2269.HK) enter into a three-year, multi-target strategic partnership to design an...
WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics
WUXI and SUZHOU, China , Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced tha...
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
SHANGHAI , July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been name...
WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment
The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders. The Company made remarkable progress in tackling ...
WuXi Biologics Reports Solid 2023 Annual Results
HONG KONG, March 26, 2024 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organiz...
WuXi Biologics Named to CDP 'A List' for Water Security
SHANGHAI , March 22, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognize...
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
SHANGHAI , March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized...
Hoping For Better Luck, HK Stocks Enter The Year Of The Dragon
Since its launch in 1969, the Hang Seng has always risen in the dragon years, with gains averaging around 14%. But any rally this time could be hampered by uncertainties over the U.S. presidential ele...
WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics
Named Top-Rated for fourth consecutive year Committed to generating long-term value for all stakeholders SHANGHAI , Feb. 21, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading globa...
WuXi Companies' Shares Slide Amid Concerns Over Proposed U.S. Bill
Shares of the WuXi family of companies extended losses amid concerns that a proposed bill in the U.S. would block the U.S. government from doing business with some Chinese biotechnology companies.
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland
- First manufacturing run successful for MFG7 facility at the Ireland site- Largest manufacturing scale to date achieved by combining four 4,000-liter single-use bioreactors DUNDALK, Ireland , Jan. ...
WuXi Bio Denies Military Ties After Shares Slumped on US Bill
WuXi Biologics Cayman Inc., one of China's leading drug contract research and manufacturing companies, said its chief executive officer has not worked for any military-affiliated institution. The stoc...
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect
- WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated cy...
WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™
SHANGHAI , Jan. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that a patent fo...
WuXi Biologics to Increase Manufacturing Capacity in Massachusetts
The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the U.S. The site is expected to employ 250 people when fully operational. WORCESTER, Mass.
WuXi Biologics Named to 2023 Dow Jones Sustainability World Index
Identified as a global sustainability leader by S&P Global Committed to generating long-term value for all stakeholders SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a...
WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating
Ranked in top 1% of the over 100,000 companies evaluated Recognized for outstanding performance across all areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement Seen as a trust...
WuXi Biologics: Holiday Fire Sale For Leading CRDMO
WuXi Biologics is a contract-based drug developer in China, but recent share price performance has lagged. The company is expecting a major miss in revenues for FY 2023 due mostly to over-optimism, ca...
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture to final UF/DF pool at pilot scale This end-to-end con...
Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics
LONDON and SHANGHAI, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugat...